Gavin Reilly
YOU?
Author Swipe
View article: Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial Open
Cancer Research UK, AstraZeneca, Wellcome Trust, and Health Technology Assessment.
View article: Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT)
Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT) Open
View article: Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: A single centre experience
Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: A single centre experience Open
View article: The changing world of clinical trials 2003-2017: A view from the AspECT trial
The changing world of clinical trials 2003-2017: A view from the AspECT trial Open
The past two decades have seen dramatic changes in clinical trial conduct and methodology. From trial regulation to data analysis, the rapid rise of randomised control trials (RCTs) has introduced many new techniques. Some methods of desig…
View article: Valuing the effect sizes hypothesized in phase 3 trials of targeted therapies in oncology
Valuing the effect sizes hypothesized in phase 3 trials of targeted therapies in oncology Open
This abstract was not included in this publication as it was already published. See Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 317P (10.1093/annonc/mdw366.02) - Oxford University Press.